AF
BBIO icon

Avanza Fonder’s BridgeBio Pharma BBIO Stock Holding History

Avanza Fonder’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,168
Closed -$319K – 489
2025
Q4 		$319K Sell
4,168
-1,571
-27% -$103K 0.01% 408
2025
Q3 		$298K Sell
5,739
-526
-8% -$25.7K 0.01% 374
2025
Q2 		$271K Buy
6,265
+144
+2% +$5.24K 0.01% 375
2025
Q1 		$212K Sell
6,121
-460
-7% -$15.5K 0.01% 412
2024
Q4 		$181K Buy
+6,581
New +$170K 0.01% 401

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avanza Fonder's BBIO Position: Q1 2026 in Review

Avanza Fonder sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 4,168 shares — an estimated $319K sold.

Avanza Fonder first reported a position in BBIO in Q4 2024 and held it in 5 quarters. The position peaked at $319K in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Avanza Fonder reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 4,168 BridgeBio Pharma shares in Q1 2026, an estimated $319K.
  • Avanza Fonder first reported a position in BridgeBio Pharma in Q4 2024 and held it in 5 quarters.
  • Avanza Fonder's BridgeBio Pharma position peaked at $319K in Q4 2025.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.